ETASCAN Project: ETAS Project 2
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age60-80
SponsorUniversity of Reading
About this trial
This study aims to investigate the chronic effects of ETAS® on cognitive, affective and neural outcomes in healthy adults aged 60-80 years with mild to moderate subjective cognitive complaints.
Eligibility criteria
Qualifiers
Aging between 60-80 years old
Having normal vision and hearing
Having a body mass index between 18.5 and 30
Having mild to moderate subjective cognitive complaints
Disqualifiers
Smoking
Having food allergies
Following restrictive and/or unbalanced diets (Appendix 6: Are you vegetarian or vegan? Yes / No; Are you currently on a weight-reducing or other special diet? Yes/No If 'Yes', please give details.)
Being diagnosed with any psychiatric or neurologic conditions (e.g. schizophrenia, depression, dementia) including eating disorders
Trial design
Treatments tested in this trial
- ETAS®
- Placebo
Treatment groups
60 Participants
are divided into 2 treatment groupsSponsors and collaborators
University of Reading
Lead sponsor
Amino Up Chemicals Co., Ltd.
Collaborator
Source ClinicalTrials.gov